Duncan Ross, Ph.D. Joins Global Stem Cells Group Advisory Board
Molecular biologist, immunologist and researcher Duncan Ross, Ph.D., founder of Kimera Labs, has joined the Global Stem Cells Group Advisory Board faculty.
Global Stem Cells Group CEO Benito Novas announced that Duncan Ross, Ph.D. has joined the GSCG Advisory Board. Ross is the founder of GSCG affiliate Kimera Labs in Miami.
In 2004, Ross received his Ph.D. in Immunology from the University of Miami, where he studied hematopoietic stem cell transplantation for hematologic disorders and the suppression of graft vs. host disease (GVHD) under UM Professor Robert Levy Ph.D. Ross was motivated to study in this field after witnessing his father’s experience suffering through unsuccessful treatments for Acute Myeloid Leukemia.
Since launching his career in 2004, Ross has investigated various methods of immune suppression, from regulatory T cells to post transplant cyclophosphamide, in collaboration with the Leo Luznik Transplant Lab at Johns Hopkins University in Baltimore, Maryland. The collaboration led to multiple publications in peer-reviewed journals, including “Blood” and “Biology of Blood and Marrow Transplantation 1,2.”
Ross’s interest in the use of mesenchymal stem cells (MSCs) for immune suppression stemmed from this work and the work of others in the use of MSCs to treat GVHD.
In 2008, Ross founded Kimera Labs in Miami, currently focused on the use of MSCs for the suppression of various immune mediated pathologies and regenerative medicine in the US, Latin America, and the Bahamas.
Ross recently obtained Institutional Review Board (IRB) approval to perform a patient sponsored clinical trial for chronic obstructive pulmonary disorder (COPD) using mesenchymal stem cells purified from fat, through the Kimera Society. Kimera Labs in association with Global Stem Cells Group plans to apply the same approach to diabetes and other autoimmune diseases.
Ross joins a group of esteemed stem cell researchers and physicians on the Global Stem Cells Group Advisory Board, who contribute their expertise and provide strategic advice for the management of the international biotech company.
To learn more, visit the Global Stem Cells Group website, email bnovas(at)stemcellsgroup(dot)com, Or call +1 305 560 5337.
About Global Stem Cell Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.
To view this press release live online, click here